1[10] Ringoir S: An update on uremic toxins[J]. Kidney Int,1997,52(s62):s2-s4.
2[11] Rosemary O,Brian PS,Richard AW,et al. Maintaining blood compartment volume in dialyzers reprocessed with peracetic acid maintains Kt/V but not β2-microglobulin removal[J]. Am J Kid Dis,1997,30(4):501-506.
3[1] Sethi D, Gower PE.β2-microglobulin levels, dialysis arth-ropathy and the effect of dialyzer membrane[J]. Nephrol Dial Transplant,1988,3:768-772.
4[2] Caverle Y,Simon P,Ang KS,et al. Serum β2-microglobulin levels in hemodialysis uremia depending on permeability of dialysis membranes[J]. Kidney Int,1987,31:229(abstrac).
5[3] Maidment J,Peter SJ. The dialysis prescription: reuse[J]. Am J Nephrol,1996,16:52-59.
6[4] Petersen J,Moore RM,Kaczmarek RG,et al. The effects of reprocessing cuprophane and polysulfone dialyzers on β2-microglobulin removal from hemodialysis patients[J]. Am J Kidney Dis,1991,17(2):174-178.
7[5] Diaz RJ,Washburn S,Cauble L,et al. The effects of dialyzers reprocessing on performance and β2-microglobulin removal using polysulfone membranes[J]. Am J Kidney Dis,1993,21(4):405-410.
8[6] Westhuyzen J,Foreman K,Battistutta D,et al. Effect of dialyzer reprocessing with Renalin on serum beta-2-microglobulin and complement activation in hemodialysis patients[J]. Am J Nephrol,1992,12:29-36.
9[7] Kerr PG,Argiles A,Canaud B,et al. The effects of reprocessing high-flux polysulfone dialyzers with peroxyacetic acid on β2-mecroglobulin removal in hemodiafiltration[J]. Am J Kidney Dis,1992,19(5):433-438.
10[9] Raymond V,Reta DS. Pathophysiologic effects of uremic retention solutes[J]. J Am Soc Nephrol,1999,10:1815-1823.
